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EFFECT OF CELIAC DISEASE ON GLYCEMIC CONTROL AMONG 
SUBJECTS WITH AUTOIMMUNE-INSULIN-DEPENDENT DIABETES 
ALI ALDOUKHI 
ABSTRACT 
 Purpose: The aim of this study was to determine whether glycemic control is 
different between subjects who screened negative for Celiac Disease (CD) compared 
to subjects who screened positive for CD among subjects with autoimmune insulin-
dependent diabetes. Also, this study investigated if the presence of specific beta cell 
autoantibodies, GAD65, Islet cell antibodies or both, could predict the risk for 
positive CD screening. 
 Methods/Procedures: A retrospective cohort study of an existing clinical care data 
was obtained from the Clinical Data Warehouse (CDW) in Boston Medical Center 
(BMC) for the period between January 2000 and November 2015. The exposed 
cohort included those who screened positive for CD, while the non-exposed cohort 
included subjects who screened negative for CD. The following data was collected 
and included in the analysis: demographic variables, A1C levels, Diabetic 
Ketoacidosis (DKA) events, diabetes-associated antibodies, CD screening tests, and 
CD biopsy results. Longitudinal data for each subject was obtained from the CDW. 
 Results: The prevalence of potential CD in this study was 8.8%, while the 
prevalence of biopsy confirmed CD was 4.4%. Mean A1C level for subjects who 
screened negative for TTG was 8.9% (CI 8.3 - 9.6), while mean A1C levels for 
subjects who screened positive for TTG was 7.9% (CI 6.8 - 9.0) after adjusting for 
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confounders using the mixed-effect model. This difference was not statistically 
significant. Moreover, diabetes-associated antibodies did not predict the risk for 
positive TTG screening. 
 Conclusion: The glycemic control for subjects who screened negative for CD was 
found to be similar to subjects who screened positive for CD. However, further 
studies with higher power and larger sample size are needed to confirm the findings 
of this study. 
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INTRODUCTION 
 
Diabetes Mellitus 
 Diabetes is a metabolic condition characterized by an abnormal blood glucose 
concentration either due to insulin deficiency or insulin resistance.1 Diabetes is 
categorized into four major categories, including: type1 diabetes, type2 diabetes, 
gestational diabetes, and diabetes secondary to other causes. Type1 and type2 diabetes 
are the most common types with type1 accounting for 5-10% of the cases and type2 
accounting for approximately 90% of the cases.1 As with each category, the etiology is 
different for the type of diabetes.  	 Type1 diabetes occurs due to autoimmune destruction of the pancreatic beta cells, 
which are responsible for sensing glucose concentration in the blood and secreting insulin 
from the pancreas.2,3 Moreover, type1 is further classified into type1A, immune 
mediated, and type1B, idiopathic, depending on the presence or absence of diabetes 
related autoimmune antibodies in the blood.1,4 Diabetes related autoimmune antibodies 
include islet cells autoantibodies, Glutamic Acid Decarboxylase (GAD65), tyrosine 
phosphatase IA-2 and IA2, and Zinc transporter 8(ZnT8). 
 The second type of diabetes is type2 that occurs due to insulin resistance 
characterized by an initial compensatory increase in insulin secretion in response to 
hyperglycemia, followed by relative insulin deficiency.1,2 Insulin resistance occurs early 
in the course of the disease when tissue sensitivity to insulin is reduced resulting in 
reduced glucose uptake by the liver, muscles, and adipose tissue.2 This reduction in 
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glucose uptake leads to an increase in insulin secretion from the pancreas 
(hyperinsulinemia) to increase the cellular uptake of glucose. Consequently, over a highly 
variable time period, the pancreas fails to secrete enough insulin to maintain euglycemia.2 
Moreover, scientists have recently discovered different subtypes of diabetes.  
 Latent Autoimmune Diabetes of the Adults (LADA) and Maturity Onset Diabetes 
of the Young (MODY) are some of the other subtypes of diabetes. LADA has features of 
both type1 and type2 diabetes. It resembles type1 diabetes in terms of the presence of 
autoimmune antibodies and type2 in terms of lack of insulin need at the time of 
diagnosis.5 Therefore, there are criteria for LADA diagnosis based on the following: 
development of diabetes at an adult age (between 25 and 40 years), the presence of 
autoimmune antibodies, and absence of insulin requirement for at least 6 months after 
diagnosis.5 On the other hand, Maturity Onset Diabetes of the Young (MODY) or 
monogenic forms of diabetes is another subtype of diabetes that resemble type 1 or type 2 
diabetes in which there is reduced insulin secretion usually in the absence of obesity and 
insulin resistance and is different from type1 diabetes due to absence of autoimmune 
antibodies.6 MODY is an autosomal dominantly inherited single gene disorder with high 
penetrance in affected families that results in altered beta cell function. It typically affects 
young individuals but the age of diagnosis varies widely.6 Consequently, the 
classification of diabetes keeps growing with time. 
 The growing list of different diabetes types and subtypes has made the current 
classification system for diabetes difficult to translate into clinical care.7-9 Patients 
sometimes present with features from multiple types of diabetes making the management 
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of their condition difficult. Therefore, physicians are now asking for a change to the 
current classification system so as to accommodate the various subtypes in order to 
improve patients' clinical care.10  
 The main issue with diabetes regardless of its type is elevated blood glucose 
concentration, so the main treatment goal for diabetic patients is to control their blood 
glucose concentration.1 When the patient's blood glucose concentration is controlled at 
certain level, he/she is regarded to have achieved glycemic control. There are two 
methods to monitor glycemic control: patient self-monitoring of blood glucose (SMBG) 
and glycated hemoglobin (A1C) measurement.11 In SMBG, patients record their blood 
glucose concentration at different times throughout the day to assess whether or not they 
met their glycemic targets. This tool helps patients and physicians set some treatment 
goals that can be reviewed at each visit.11 SMBG helps physicians in assessing day-to-
day variability of blood glucose concentration. On the other hand, A1C is a blood test 
that reflects the average blood glucose concentration over several months. A1C goal, in 
general, for adult males and non-pregnant females is <7% and for children and 
adolescents is <7.5%. However, these goals can be set at different levels based on each 
individual need and disease comorbidities.11 Regular testing of A1C is important as it can 
predict the risk for developing diabetes complications.11 
 Diabetes is associated with increased risk for microvascular and macrovascular 
complications. Microvascular complications affect the small arteries and include 
retinopathy, nephropathy, and neuropathy.12,13 While macrovascular complications affect 
the large arteries leading to atherosclerosis in cardiac, cerebral, and peripheral 
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vessels.12,13 Moreover, risk for developing diabetes complications depends on the 
duration of diabetes and glycemic control; the longer the duration and the worse the 
glycemic control, the higher the risk for diabetic complications.12 Accordingly, this risk 
can be mitigated by tight control of blood glucose concentration.12,14 In addition to 
increased risk for microvascular and macrovascular complications, certain types of 
diabetes are also associated with increased risk for other autoimmune conditions. 
 
Diabetes and Autoimmune Conditions 
 Type1 diabetic patients are at increased risk for developing other autoimmune 
conditions. For instance, they are at higher risk for developing autoimmune thyroiditis, 
celiac disease, pernicious anemia, adrenal autoimmunity, vitiligo, and non-organ specific 
autoimmune diseases.15 Autoimmune thyroiditis is the most common autoimmune 
condition associated with type1 diabetes; the prevalence of positive anti-thyroid antibody 
ranges from 12% to 23% which is two to four times higher than the general population. 
Likewise, celiac disease (CD) has a higher prevalence among type1 diabetic subjects. The 
prevalence of CD among type1 diabetics ranges between 3 and 16%, which is higher than 
the prevalence of CD in the general population.16 
 The aforementioned increase in prevalence of CD in patients with type1 diabetes 
can be explained by shared and overlapping genetic and environmental factors.16,17 First, 
both conditions are associated genetically with a high frequency of HLA-DR3 (Human 
Leukocyte Antigen) genotype.16,17 HLA-DR3 is found in 90% of patients with CD and in 
55% of patients with type1 diabetes.16 Second, some environmental factors have also 
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been shown to be associated with both conditions. For example, infant feeding practice, 
viral infections, and gut microbiome are among these environmental factors. Before 
exploring the effect of CD on type1 diabetic patients, it would be helpful to discuss celiac 
disease. 
 
Celiac Disease 
 The prevalence of CD in the general population is approximately 1%, and it is 
thought to be underestimated because of under-diagnosis; approximately 85% of the 
cases are not diagnosed in the US.18 
 Celiac disease (CD) is an autoimmune and inflammatory condition affecting the 
small intestine that is characterized by gastrointestinal and extra-intestinal signs and 
symptoms.18,19 Gastrointestinal presentation includes diarrhea, anorexia, vomiting, failure 
to thrive, abdominal pain, and constipation. While extra-intestinal presentation includes 
constitutional, hematologic, dermatologic, oral, musculoskeletal, hepatologic, 
endocrinologic, neurologic, and psychiatric manifestations.18,19 These signs and 
symptoms are triggered by exposure to gluten. However, not all patients are symptomatic 
for CD; some patients are asymptomatic but still can be diagnosed with CD (silent CD). 
For this reason, screening is recommended for symptomatic and asymptomatic patients 
who are at high risk for CD, such as patients with type1 diabetes or autoimmune 
thyroiditis.18,19 
 CD diagnosis is made in two steps. The first step is screening for CD 
antibodies.18,19 There are several antibodies that can be used for CD screening, including: 
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anti-tissue transglutaminase antibodies (TTG), anti-endomysium antibodies (EMA), anti-
gliadin antibodies (AGA), and deamidated gliadin peptide antibodies (DGP). In general, 
TTG and EMA should be considered as the first screening option because both have a 
sensitivity and specificity of more than 90%.18,19 The second step in the diagnosis is 
duodenal biopsy for patients who screen positive for CD to confirm the diagnosis.18,19  
 After confirming the diagnosis, the patient should be treated for CD. Because CD 
is triggered by exposure to gluten, the treatment option would be Gluten Free Diet 
(GFD). Patients who adhere to GFD will usually experience improvements in their 
symptoms.18,19 GFD is the only current treatment option, but more treatment options are 
under investigation.19  
 As stated earlier, patients with type1 diabetes are at increased risk for developing 
CD.15 For this reason, the effect of CD on type1 diabetes and early detection of CD in 
patients with type1 diabetes need to be explored. 
 
Diabetes Complications for Patients with Type1 Diabetes CD 
 The risk for developing diabetic microvascular complications (retinopathy, 
nephropathy, and neuropathy) in subjects with both CD and type1 diabetes, compared to 
subjects with only type1 diabetes, varies among studies.20-25 Some studies found an 
increased risk for microvascular complications for subjects with both conditions. For 
example, Leeds et al found that type1 diabetic subjects with newly diagnosed, biopsy-
confirmed CD had a higher prevalence of retinopathy, nephropathy, and peripheral 
neuropathy compared to subjects with type1 diabetes alone. The difference was 
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significant for retinopathy and nephropathy but not for neuropathy.20 Similarly, 
Mollazadegan et al found an increased risk for diabetic retinopathy among type1 diabetic 
subjects with biopsy-confirmed CD.21 In a second study by Mollazadegan et al, the risk 
for diabetic nephropathy was examined in the same cohort of biopsy-confirmed CD 
versus type1 diabetics. Overall, Mollazadegan found that neither groups were at an 
increased risk for renal complications.22 However, in Mollazadegan studies time since 
CD diagnosis played an important role in the risk of developing microvasular 
complications. Also, a study conducted by Rohrer et al found that subjects who screened 
positive or had positive biopsy for CD were at higher risk for developing retinopathy and 
neuropathy.23   
 On the other hand, some studies did not find increased risk for microvascular 
complications between subjects who had CD and type1 diabetes compared to subjects 
who had type1 diabetes alone. For instance, a second study by Leeds et al examined the 
prevalence of diabetes complications in subjects who had positive CD antibodies with 
normal duodenal biopsy (potential CD), and subjects with diabetes alone. In this study 
the prevalence for retinopathy or neuropathy was similar in both groups.24 Likewise, 
Bakker et al found lower prevalence of retinopathy in subjects with both CD and type1 
diabetes compared to subjects with only type1 diabetes (39% and 67%, respectively) but 
found no difference in the prevalence of nephropathy between the two cohorts.25  
 The risk for developing diabetic macrovasular complications has also been 
examined in subjects with both type1 diabetes and CD.26 Pitocco et al found that subjects 
with both conditions had higher cIMT (carotid intima media thickness) compared to 
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subjects with only type1 diabetes, which increase their risk for macrovascular 
complications.26 Carotid Intima Media Thickness is a non-invasive ultrasonographic 
measurement of the carotid artery thickness that has been shown to estimate the risk for 
myocardial infarction and stroke in patients with no history of cardiovascular disease.27 
The findings by Pitocco et al, however, need to be confirmed by other studies. 
 As stated earlier the risk for developing diabetes related complications highly 
depends on the patient's glycemic control, and that it can be mitigated by tight control of 
blood glucose levels.12,14 So, the differences in diabetes complications risks that were 
reported in the previous studies could be explained by differences in glycemic control 
between the two study groups. 
 
Glycemic Control for Patients with Type1 Diabetes and CD  
 The effect of CD on glycemic control in subjects with type1 diabetes varies 
between the studies.20,25,28-31 First of all, in a study by Leeds et al subjects with CD and 
type1 diabetes had worse glycemic control at baseline, as measured by glycated 
hemoglobin (A1C), compared to subjects with only type1 diabetes before the initiation of 
Gluten Free Diet (GFD).20 Second, other studies found that subjects with both conditions 
had better glycemic control. For example, Sun et al found that subjects with CD and 
type1 diabetes had lower A1C before CD diagnosis and before the initiation of GFD.28 
Similarly, Mackinder et al found that at the time of CD diagnosis subjects who were 
diagnosed with CD had significantly lower A1C than subjects who were not diagnosed 
with CD.29 Lastly, other studies found no difference in glycemic control between the 
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groups: diabetes and CD versus diabetes alone.25,30,31 There are still gaps in our 
knowledge of the true effect of CD on glycemic control. Because of the possible negative 
effects of CD in type1 diabetics, there are recommendations to screen type1 diabetics 
routinely for CD. 
 
Screening Recommendations for CD in Patients with Type1 Diabetes 
 The 2005 North American Society of Pediatric Gastroenterology, Hepatology, 
and Nutrition (NASPGHAN) guidelines recommend CD screening for the general 
population and for asymptomatic patients who are at high risk for CD such as type1 
diabetic patients.32 These guidelines recommend that physicians perform an initial 
screening with TTG with directions as to the next steps depending on the initial screening 
results.  
 If the initial TTG test is positive for CD, the patient should be referred to a 
gastroenterologist for duodenal biopsy. If the initial duodenal biopsy is positive, the 
patient should be started on Gluten Free Diet (GFD). If the duodenal biopsy is negative, 
the guidelines recommend repeating the biopsy, EMA test, or Human Leukocyte Antigen 
(HLA) test. Conversely, if the initial TTG is negative, repeating the test over a period of 
time or HLA testing should be considered. The guidelines do not specify the time interval 
between each TTG test. However, patients with negative HLA tests should be reassured 
that no additional testing is needed.  
 In response to the earlier guidelines, the European Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition (ESP-GHAN) has released their 2012 
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guidelines for CD diagnosis. This revised version includes new guidelines for CD 
screening and diagnosis in asymptomatic patients with type1 diabetes.33 The first step for 
an asymptomatic child or adolescent with type1 diabetes is to screen him/her for HLA-
DQ2 and/or DQ8. If the results are negative, there is no anticipated risk for CD. 
Conversely if the results are positive, the guidelines recommend that the patient be 
screened for TTG with IgA level determination. If TTG is negative, the patient should 
then be rescreened every 2-3 years. However, if TTG is positive and 3 times higher than 
the upper normal limit, the guidelines recommend that the patient undergo a duodenal 
biopsy to confirm the diagnosis; if TTG is positive but less than 3 times the upper normal 
limit, EMA testing should be considered. If EMA is positive, the guidelines recommend 
that the patient undergo a duodenal biopsy to confirm the diagnosis. If EMA is negative, 
repeating the TTG test every 3-6 months until either the levels return to normal or the 
levels rises to more than 3 times higher than the upper normal limit is recommended.33  
 The American College of Gastroenterology (ACG) and the American Diabetes 
Association (ADA) have different positions when it involves screening patients with 
type1 diabetic for CD.34 The ACG recommends screening for patients who are either 
symptomatic for CD or have a family history of CD or type1 diabetes. Similarly, the 
ADA recommends screening type1 diabetic patients for CD at the time of diabetes 
diagnosis and between 2-5 years following the diagnosis. More specifically, the ADA 
recommends that screening should be considered "in children who have a first-degree 
relative with celiac disease, growth failure, weight loss, failure to gain weight, diarrhea, 
flatulence, abdominal pain, or signs of malabsorption or in children with frequent 
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unexplained hypoglycemia or deterioration in glycemic control".35 However, it is 
important to note that the ADA assigned a grade of "E" to this recommendation; grade A 
represents the highest level of evidence that is given for well-conducted randomized-
controlled clinical trials, while grade E is the lowest level that is given for 
recommendations that come from expert consensus or clinical experience.  
 The guidelines discussed earlier vary when it comes to the frequency of CD 
screening. Thus, several prospective and retrospective cohort studies have been 
conducted to examine the optimal time and intervals to screen for CD in subjects with 
type1 diabetes.36-41 A summary of these studies is provided in table 1 and the following 
are highlights for the findings of these studies: the study population in most of the studies 
was under the age of 18 years; the most common screening test used was EMA; the 
longest follow up period was 19 years; the presence or absence of diabetes autoantibodies 
was partly assessed in some of the studies; and, the mean duration from the time of 
diabetes diagnosis until the time of positive CD screening was 3 years in most of the 
studies. Accordingly the majority of the studies recommended annual screening for CD.  
 Moreover, Tiberti et al reported data from a cross-sectional study that looked at 
the association of CD among subjects with long standing diabetes.42 This study included 
277 subjects with type1 diabetes (mean age 41.7 years and mean diabetes duration 23.4 
years) who were screened for CD using TTG and DGP. In this study, 17 subjects (6.1%) 
screened positive for CD, so the authors recommended that screening should be 
considered even after 15 years of diabetes duration. This observation has also been 
highlighted in a recent meta-analysis in which the authors concluded that there is a need 
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for more research in adult subjects and disease duration of more than 5 years.43 Thus, 
more studies are needed to examine the effects of diabetes autoantibodies and long 
standing diabetes on the screening frequency for CD. 
 
Table 1. Summary of the Studies that Investigated the Frequency of CD screening 
First 
Author, 
Year 
Number 
of 
subjects 
Mean age 
at the 
beginning 
of the 
study 
CD 
screening 
test used 
Number 
of 
subjects 
with 
positive 
screening  
Time 
from 
diabetes 
diagnosis 
to positive 
CD 
screeninga 
Recommendation 
Glastras et 
al, 2005 
 
173 8.2 (range 
0.9 - 14.9) 
EMA 8 (4.6%)b  3.6 year 
(range 2.8 
- 10.2 
years) 
Screening at 2 
years interval 
Crone et al, 
2003 
 
157 14.8 
(range 4 - 
21) 
EMA 16 
(10.2%)c 
23.9 
months 
(range 11 - 
105 
months) 
Annually 
Larsson et 
al, 2008 
 
300 9.2 (range 
1.3 - 18.7) 
EMA 29 (10%)d 1.9 years 
(range 1 - 
5 years) 
Annually for at 
least 2 years 
Pham-Short 
et al, 2012  
 
4,379 <18 years 
of age 
EMA, 
TTG 
185 
(4.2%)e 
See belowf Annually for at 
least 10 years 
Berera et al, 
2002 
 
274 8.28 
(range 0.6 
- 18.7) 
EMA 32 (11.7 
%)g 
- Annually 
Salaradi et 
al, 2008 
331 8.1 (range 
0.08 - 
14.9) 
EMA 31 
(9.3%)h 
Range 
0.75 - 6 
years 
- 
a Data is only for subjects who screened positive during the follow up period. 
b 4 at the time of diabetes diagnosis and 4  during the follow up. 
c 5 at the time of diabetes diagnosis and 11 during the follow up. 
d 2 Before the time of diabetes diagnosis, 10 at the time of diabetes diagnosis and 17 during the follow up. 
e 124 at the time of diabetes diagnosis and 61 during the follow up. 
f 3 years (range 0.1 - 14.4) for children diagnosed with diabetes at <5 years, 2.1 years (range 0.1 - 10) for 
children diagnosed with diabetes between 5 - 10 years, and 0.7 years (range 0.2 - 3.8) for children 
diagnosed with diabetes >10 years of age.  
g 15 at the time of diabetes diagnosis and 17 during the follow up. 
h 2 Before the time of diabetes diagnosis, 15 at the time of diabetes diagnosis and 14 during the follow up. 
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Study Rationale 
 Understanding the effect of CD on glycemic control would help in diabetes 
management for patients who are diagnosed with both diabetes and CD. Glycemic 
control plays a major role in the development of diabetes related complications, and tight 
control of blood glucose concentrations can reduce the risk for diabetes complications.12 
If subjects with both conditions have worse glycemic control than subjects with diabetes 
only, then this would help future scientists to explore the reasons behind the effect of CD 
on glycemic control. Also, the results will help to guide physicians at the moment in 
taking the appropriate measures to help patients with both conditions to achieve better 
glycemic control. Moreover, this study will explore the frequency at which diabetic 
patients should be screened for CD. This could help in promoting CD screening for 
pediatric (<18 years) and adult patients (>18 years).  
 
Primary Objective 
• To determine whether glycemic control is different between subjects who 
screened positive for CD compared to subjects who screened negative for CD. 
Secondary Objectives 
• To determine if the presence of specific beta cell autoantibodies, GAD65, Islet 
cell antibodies or both, predicts positive CD screening results. 
• To determine the screening frequency for CD in pediatric and adult populations 
with autoimmune-insulin-dependent diabetes. 
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METHODS 
Study Design 
 This was a retrospective cohort study that analyzed existing clinical data obtained 
from patients seen at the Boston Medical Center (BMC) between January 2000 and 
November 2015. The exposed cohort included those who screened positive for CD, while 
the non-exposed cohort included subjects who screened negative for CD. The study 
outcome was glycemic control exhibited by these cohorts between January 2000 and 
November 2015. Data was obtained from the Clinical Data Warehouse (CDW) at the 
Boston Medical Center (BMC). CDW is a department that houses a database of clinical 
data and patient information available from different departments within BMC that can 
be used for different purposes, including research.44 This study was approved by the 
Boston University Medical Campus (BUMC) Institutional Review Board (IRB). 
 
Study Population 
 The study population was defined based on the following inclusion and exclusion 
criteria:  
Inclusion criteria included: 
• Age under or above 18 years old. 
• Clinical diagnosis of diabetes based on the American Diabetes Association 
(ADA) criteria, defined by having one of the following: A1c ≥6.5%; fasting 
plasma glucose ≥126 mg/dl; oral glucose tolerance test glucose value two hours 
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after 75 gram glucose load ≥200mg/dl; or a random plasma glucose ≥200mg/dl 
with classical symptoms of hyperglycemia.1 
• A positive type1 diabetes associated antibody test defined by having one of the 
following: positive islet cell antibody test (positive immunofluorescence assay); 
positive GAD65 antibody test (>1.0 U/mL); or positive tyrosin phosphatase IA-2 
antibody test (≥0.8 U/mL). 
• Insulin use for the management of diabetes. 
• At least one CD screening test following the diagnosis of diabetes using the 
Gliadin, EMA or TTG test. 
Exclusion criteria: 
• No diabetes diagnosis on the subject's problem list. 
• CD screening before diabetes diagnosis.  
 
 The clinical assessments for CD and glycemic control, described below, were 
both performed for clinical care, not for research purposes. Only the deidentified data 
obtained from these clinic visits were used in this study. 
 
Clinical Assessment of CD  
 Diagnosis of CD was obtained from both the CD screening tests and CD biopsy. 
Screening tests used for the diagnosis of CD included Gliadin (IgA) antibody test 
(positive was ≥20 Units), EMA (IgA) test (positive was positive immunofluorescence 
assay), and TTG (IgA) antibody (positive was ≥4 U/mL). CD biopsy data was obtained 
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from duodenal biopsy reports of samples acquired during an upper gastrointestinal 
endoscopy. In these reports pathological findings consistent with CD were considered a 
positive CD biopsy. Subjects who screened positive for CD were considered to have 
potential CD, while subjects who screened positive for CD and had a positive CD biopsy 
were considered to have confirmed CD. Lastly, data for the duration of time from the 
diagnosis of diabetes to time of CD screening test was obtained for each screening test. 
 
Clinical Assessment of Glycemic control  
 Glycemic control was assessed via A1C concentrations. In clinical practice, the 
frequency of A1C testing depends on the patient's glycemic control and individualized 
goals, typically ranging from 2 to 4 times a year.11 For this reason, the intervals between 
the measurements of A1C concentrations in the data were not the same for each subject; 
however, all A1C levels performed at BMC were included in the analysis for this study.  
 
Study Measures 
 In addition to the predictor variable, CD screening, outcome variable, A1C levels, 
and the inclusion/exclusion criteria used to define the study population, additional 
variables were obtained from the CDW for this study including: number of diabetic 
ketoacidosis (DKA) events as reported on the subject's problem list; follow-up duration 
as was defined as the duration between the first and last A1C performed at BMC; and 
IgA serum level. Moreover, age was defined as the age at which diabetes was diagnosed. 
This information was obtained via the CDW from the subject's medical history. However, 
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if the age at diabetes diagnosis was unavailable in the medical history, then the age at 
first visit to BMC to establish diabetes care was used as the age of diabetes diagnosis. 
 
Statistical Analysis 
 Descriptive statistics were used to assess the baseline measures for each study 
cohort. Baseline measures were compared between the two study cohorts using Fisher's 
exact test for categorical variables and Student's t-Test for continuous variables. 
 
Primary objective analysis (glycemic control): 
 As A1C data was collected longitudinally, two statistical methods that account for 
repeated measures were used for the analysis. The difference in glycemic control between 
the two cohorts was compared using Generalized Estimating Equations (GEE) and 
mixed-effects models. Initially, non-adjusted models were used to look at the difference 
in mean A1C levels over the study period between the two cohorts. Then the models were 
adjusted by controlling for age and number of DKA events. P-value of <0.05 was 
considered to be statistically significant. Furthermore, an interaction term to test for effect 
modification of time since enrollment on the relationship between CD screening and A1C 
levels was used for each model. 
 
Secondary outcomes analysis 
 Relative risk and 95% confidence interval was used to determine if the presence 
of diabetes antibodies predicted CD screening results. Three predictors were used for this 
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analysis, including GAD65, Islet cell antibodies, and a combined predictor for both 
GAD65 and Islet cell antibodies. Furthermore, a p-value was calculated using Fisher's 
exact test and a p-value of <0.05 was considered to be statistically significant. 
 Another objective for this study was to determine the screening frequency for CD 
in pediatric and adult subjects with autoimmune-insulin-dependent diabetes. Due to small 
sample size and short follow up for subjects who had multiple CD screening tests, only 
descriptive statistics were used to explore this objective. Subjects were considered to 
have multiple CD screening test if the duration between two consecutive screening tests 
was > 1 month. Additionally, a complete list of subjects who had multiple TTG 
screenings was reported separately. 
 All statistical analysis was conducted using R. 
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RESULTS 
 
Study Population 
 Data for 343 subjects who were seen during the study period and had positive 
type1 diabetes-associated antibodies was obtained from the CDW. Seven of the 343 
subjects were excluded because they did not have diabetes on their problem list, and an 
additional 31 subjects were excluded because they were not insulin dependent. 
Furthermore, 234 were excluded because they were not screened for CD and one subject 
was excluded because CD screening was performed before diabetes diagnosis. Thus, the 
study cohort consisted of 70 subjects with antibody confirmed, insulin dependent type1 
diabetes, who were screened at least once for CD after diabetes diagnosis (Figure 1). 
Analysis comparing subjects who were screened for CD to subjects who were not 
screened is provided in the appendix (Table A1). 
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Figure 1. Flowchart for Data Received From the CDW and Data Included in the 
Analysis. Green boxes indicates study cohort 
 
Overall Baseline Characteristics 
 Table 2 highlights the overall baseline characteristics for the 70 subjects who met 
the inclusion and exclusion criteria. As shown, more than half of the subjects were 
female, all subjects were using insulin, and the majority of subjects were GAD65 
positive. Also, the overall median age at diabetes diagnosis was 17 years and the overall 
median follow up duration was 3.4 years. IgA level was available for 38 out of the 70 
subjects with a median level of 190.5 mg/dL (range 8 - 464 mg/dL).  
 The dissemination of baseline variables is provided in Figure 2. Age at diabetes 
diagnosis was not normally distributed (skewed to the right) with more subjects on the 
left half of the histogram compared to the right half. Seven subjects were between the 
343	subjects	with	positive	diabetes	antibodies	 • 	7	were	not	diagnosed	with	diabetes	
336	were	diagnosed	with	diabetes	 • 	31	were	not	insulin	dependent	
305	were	insulin	dependent	 • 	234	were	not	screened	for	CD	• 	One	was	screened	for	CD	before	diabetes	diagnosis	
70	were	screened	for	CD	
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ages of 40 and 60 years. Similar to age, follow up duration was not normally distributed 
(skewed to the right), and the majority of subjects had less than 5 years of follow up 
duration. Serum IgA level was normally distributed with two subjects having levels of 
more than 400 mg/dL. Because most of the data was skewed, median and interquartile 
ranges (IQR) were used to summarize the data. 
 
 Table 2. Baseline Characteristics 
Variable Results 
Sex  
Female N (%) 
 
36 (51%) 
Age 
Median (IQR) 
Overall 
Pediatric (<18) 
Adults (≥18) 
 
 
17 years (16.3) 
11 years (8) 
27 years (12.75) 
Insulin  
N (%) 
 
70 (100%) 
DKA 
N (%) 
 
33 (47%) 
Diabetes antibodies 
N (%) 
GAD65 positive 
Islet cell antibodies positive 
GAD65 and Islet cell antibodies positive 
 
 
56 (80%) 
5 (7%) 
9 (13%) 
Follow up duration  
Median (IQR) 
Overall 
Pediatric 
Adults 
 
 
3.4 years (7.5) 
2.5 years (4) 
5 years (9) 
 
	22 
 
Figure 2. Distributions of Baseline Characteristics for the Study Cohort 
 
 A detailed description of CD screening test is provided in Table 3. Overall, the 
majority of subjects, 68, were screened using TTG. Gliadin was used, as a screening test, 
in 11 subjects and EMA was the CD screening test performed the least, only in 8 
subjects. In general, 1 subject was positive for both Gliadin and TTG, 2 subjects were 
positive for EMA and TTG, 3 were positive only for TTG, and 1 was positive only for 
Gliadin. Because the majority of subjects were screened using TTG, the analysis was 
conducted on the 68 subjects who were screened for TTG. 
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Table 3. CD Screening Tests and Results 
Screening test Number of subjects Results* 
Gliadin & TTG & EMA 1 • 1 negative for all 
Gliadin & TTG 8 • 1 positive for both 
• 1 positive for TTG and 
negative for Gliadin 
• 1 positive for Gliadin 
and negative for TTG 
• 5 negative for both  
TTG & EMA  7 • 2 positive for both 
• 5 negative for both 
TTG  52 • 2 positive 
• 50 negative  
Gliadin  2 • 2 negative 
* Results are provided for each group of subject  
 
Overall Celiac Disease Prevalence 
 Sixty-eight subjects were screened at least once for TTG after being diagnosed 
with diabetes. Median time between diabetes diagnosis and first TTG screening was 37.5 
months (IQR 127.5 months). Six of the 68 subjects screened positive for TTG (potential 
CD). Of the 6 subjects who screened positive for TTG, 4 subjects underwent duodenal 
biopsy; 3 subjects were positive and one subject was negative for CD. Therefore, the 
prevalence of potential CD in this cohort was 8.8%, while the prevalence of confirmed 
CD was 4.4%.  
 Baseline characteristics based on TTG status are provided in Table 4. 
Approximately half of the subjects in each cohort were females. Subjects who screened 
positive for TTG were older (median age 22 years) and had a longer follow-up duration 
compared to subjects who screened negative (median age 17 years); however, this 
difference was not statistically significant. Similarly, subjects who screened positive had 
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more visits because they had a longer follow-up duration compared to subjects who 
screened negative. More subjects had a history of DKA events in the negative TTG 
cohort compared to the positive TTG cohort. 
 
Table 4. Baseline Characteristics Based on TTG Screening Results 
Variable Negative TTG1  
(N=62) 
Positive TTG1  
(N=6) 
Sex  
Female N (%) 
 
33 (53%) 
 
3 (50%) 
Age a 
Median (IQR) 
 
17 years (15.25)  
 
22 years (21.75) 
DKA a 
N (%) 
  
30 (48%) 
 
2 (33%) 
Follow-up a 
Median (IQR) 
 
3.2 years (6.6) 
 
8.7 years (7.45) 
Number of visits a,b 
Median (IQR) 
 
9 visits (13.5) 
 
17 visits (7.5) 
a The difference is not statistically significant (p >0.05) 
b Visits corresponds to the visit at which A1C test was done. 
 
Glycemic Control 
 Longitudinal A1C data was available for a median of 3.2 years (range 0.1 - 16.2 
years) for subjects who screened negative for TTG and 8.7 years (range 2.2 - 15.9 years) 
for subjects who screened positive for TTG. Figure 3 shows a plot of the A1C levels for 
each subject within each cohort over the study follow-up period. Overall, the mean A1C 
level (blue line) was slightly higher for subjects who screened negative for TTG 
compared to subjects who screened positive for TTG. 95% confidence interval (red 
shadow) was narrower for subjects who screened negative for TTG because of a larger 
sample size compared to subjects who screened positive for TTG. 
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Figure 3: Plot of the A1C Results Over the Study Period for Each Subject.  
The blue line represents the mean and the red shadow represents the 95% CI 
 
Analysis Using GEE Models 
 First, the unadjusted model (Table 5) shows that subjects who screened negative 
for TTG had a mean A1C level of 9.3% (CI 8.9 - 9.7), while subjects who screened 
positive for TTG had a mean AIC level of 8.3% (CI 7.4 - 9.1) over the study period. This 
was statistically significant with a p-value of 0.01. Table 6 shows that after controlling 
for age at the time of diabetes diagnosis and number of DKA events, the difference 
between the two cohorts remained statistically significant. Moreover, each DKA event 
was associated with a 0.6% increase in mean A1C level over the study period. Even 
though the effect of age on A1C concentration was not statistically significant, it was 
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retained in the model because it was clinically relevant. Conversely, the interaction term 
for time effect on the relationship between TTG status and A1C levels was not 
statistically significant, so it was excluded from the model. 
 An additional analysis between subjects with confirmed CD (positive TTG and 
positive biopsy) and subjects with negative TTG screening test was performed. Results 
from the unadjusted model (Table 7) showed that subjects with a negative TTG had a 
mean A1C of 9.3% (CI 8.9 - 9.7), while subjects who were diagnosed with confirmed CD 
had a mean A1C of 9.1% (CI 8.5- 9.7). This was not statistically significant (p = 0.51). In 
addition, Table 8 presents the results of the adjusted model. Even though there was a 
0.5% difference in mean A1C level between the cohorts in the adjusted model, it was not 
statistically significant. However, effect of DKA events on A1C level was significant. 
 
Table 5. Unadjusted GEE Model for Subjects with Negative TTG Compared to 
Positive TTG  
 A1C level (%) 
Predictor 
variable Beta 95% CI 
Robust 
standard error P Value 
Intercepta 9.3 8.9 - 9.7 0.2 - 
TTG Positive -1.0 -1.9 - -0.2 0.4 0.01* 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
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Table 6. Adjusted GEE Model for Subjects with Negative TTG Compared to 
Positive TTG  
 A1C level (%) 
Predictor 
variable Beta 95% CI 
Robust 
standard error P Value 
Intercepta 8.8 8.3 - 9.5 0.32 - 
TTG Positive -0.9 -1.6 - -0.3 0.32 <0.01* 
Age -0.002 -0.02 - 0.02 0.009 0.8 
DKA events 0.6 0.3 - 0.8 0.13 <0.001* 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
 
Table 7. Unadjusted GEE Model for Subjects with Negative TTG Compared to 
Confirmed CD 
 A1C level (%) 
Predictor 
variable Beta 95% CI 
Robust 
standard error P Value 
Intercepta 9.3 8.9 - 9.7 0.2 - 
Confirmed CD -0.2 -0.8 - 0.4 0.3 0.5 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
 
 
Table 8. Adjusted GEE Model for Subjects with Negative TTG Compared to 
Confirmed CD 
 A1C level (%) 
Predictor 
variable Beta 95% CI 
Robust 
standard error P Value 
Intercepta 8.9 8.3 - 9.6 0.32 - 
Confirmed CD -0.5 -1.2 - 0.2 0.36 0.2 
Age -0.004 -0.02 - 0.01 0.009 0.7 
DKA events 0.5 0.3 - 0.8 0.14 <0.001* 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
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Analysis Using Mixed-Effects Models 
 Similar to the GEE model, the unadjusted mixed-effects model (Table 9) showed 
that subjects with a negative TTG screening had a mean A1C level of 9.3% (CI 8.9 - 9.7) 
while subjects who screened positive for TTG had a mean of 8.3% (CI 7.0 - 9.4) over the 
study period. However, this difference was not statistically significant (p = 0.1). Table 10 
demonstrates that after adjusting for age at diabetes diagnosis and DKA events subjects 
with positive TTG still experienced lower A1C levels compared to subject with negative 
TTG; however, this difference was not statistically significant. Subjects who had a 
history of DKA events had higher A1C levels compared to subjects who had no history 
of DKA events. Moreover, the interaction term for time effect on the relationship 
between TTG status and A1C levels was not statistically significant, so it was dropped 
from the final model. 
 A secondary analysis was conducted comparing subjects with confirmed CD 
(positive TTG and positive biopsy) to subjects with negative TTG screening test using a 
mixed-effects model. The unadjusted model (Table 11) shows that subjects with a 
negative TTG screen had a mean A1C of 9.3% (CI 8.9 - 9.7), and subjects who were 
diagnosed with confirmed CD had a mean A1C of 9.1% (CI 7.4 - 10.8). This was not 
statistically significant (p = 0.8). In the adjusted model, Table 12, the difference between 
the two cohorts after controlling for age and number of DKA events was 0.5%; however, 
it was not statistically significant (p = 0.6). Similar to the GEE model, subjects who 
experienced DKA events had higher A1C levels. 
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Table 9. Unadjusted Mixed-Effects model for Subjects with Negative TTG 
Compared to Positive TTG 
 A1C level (%) 
Predictor 
variable Beta 95% CI Standard error P Value 
Intercepta 9.3 8.9 - 9.7 0.2 - 
TTG Positive -1.0 -2.2 - 0.2 0.6 0.1 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
 
 
Table 10. Adjusted Mixed-Effects Model for Subjects with Negative TTG Compared 
to Positive TTG 
 A1C level (%) 
Predictor 
variable Beta 95% CI Standard error P Value 
Intercepta 8.9 8.3 - 9.6 0.35 - 
TTG Positive -1.0 -2.1 - 0.1 0.59 0.09 
Age -0.003 -0.02 - 0.02 0.01 0.8 
DKA events 0.5 0.2 - 0.9 0.2 <0.01* 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
 
 
Table 11. Unadjusted Mixed-Effects Model for Subjects with Negative TTG 
Compared to Confirmed CD 
 A1C level (%) 
Predictor 
variable Beta 95% CI Standard error P Value 
Intercepta 9.3 8.9 - 9.7 0.2 - 
Confirmed CD -0.2 -1.9 - 1.5 0.9 0.8 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
 
 
 
 
	30 
Table 12. Adjusted Mixed-Effects Model for Subjects with Negative TTG Compared 
to Confirmed CD 
 A1C level (%) 
Predictor 
variable Beta 95% CI Standard error P Value 
Intercepta 9.0 8.3 - 9.7 0.36 - 
Confirmed CD -0.5 -2.0 - 1.1 0.83 0.6 
Age -0.005 -0.03 - 0.02 0.01 0.7 
DKA events 0.5 0.1 - 0.9 0.2 0.02* 
a Intercept represent the mean A1C for subjects who screened negative for TTG. 
 
 
Association Between Diabetes Antibodies and CD Screening 
 For the 68 subjects who were included in the analysis, 18 subjects were screened 
for diabetes antibodies using only GAD65, 2 subjects were screened using only Islet cell 
antibodies, and 48 subjects were screened using both GAD65 and Islet cell antibodies. 
The results of the TTG screening based on diabetes antibodies tests are provided in 
Tables 13, 14, and 15. Table 13 shows that almost all of the subjects screened positive for 
GAD65 of whom 5 screened positive for TTG while 59 screened negative for TTG. 
Subjects who were positive for GAD65 compared with subjects who were negative for 
GAD65 had a relative risk of 0.16 (CI 0.001 - 8; p = 0.17) to screen positive for TTG. In 
contrast, Table 14 shows that the majority of subjects screened negative for Islet cell 
antibodies. Subjects who were positive for Islet cell antibodies compared with subjects 
who were negative for Islet cell antibodies had a relative risk of 0.95 (CI 0.02 - 13.1; p 
>0.9) to screen positive for TTG. Data for subjects who were screened for both GAD65 
and Islet cell antibodies is presented in Table 15. Most of the subjects were negative for 
both antibodies and there was no subject who was positive for both diabetes antibodies 
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and positive for TTG. Consequently, the relative risk of a positive TTG screening for 
subjects who were positive for both GAD65 and Islet cell antibodies was not calculated. 
 
Table 13. TTG Screening Results Based on GAD65 Results 
 TTG 
GAD65 Positive Negative 
Positive 5 59 
Negative 1 1 
 
Table 14. TTG Screening Results Based on Islet Cell Antibodies Results 
 TTG 
Islet cell antibodies Positive Negative 
Positive 1 12 
Negative 3 34 
 
Table 15. TTG screening results based on both GAD65 and Islet Cell Antibodies 
results 
 TTG 
GAD65 and Islet cell antibodies* Positive Negative 
Positive 0 9 
Negative 4 35 
* Negative means the subject was positive only for one test and positive means the subject was positive for 
both tests 
 
Screening Frequency for CD 
 Thirteen of the 68 subjects who were screened for TTG in this cohort had more 
than one screening for TTG. For this reason, only descriptive statistics were reported with 
no formal statistical testing. Table 16 summarizes the data for the 13 subjects with a more 
detailed synopsis provided in Table 17. As shown, less than half of the subjects were 
female, the median age at diabetes diagnosis was 18 years, and most of the subjects 
	32 
screened positive for GAD65. As expected, subjects in this subset had a longer median 
follow up duration than subjects from the main cohort (5.3 vs. 3.4 years). In addition, the 
median duration between first TTG screening to second TTG screening was longer than 
the median duration between diabetes diagnosis and first TTG screening. IgA level was 
measured in 9 subjects with a median of 191 mg/dL (range 53 - 464). 
 Regarding TTG screening tests results, 3 subjects screened positive at their first 
TTG screening, while 2 of the 3 subjects remained positive at the second TTG screening. 
None of the subjects who screened negative at their first TTG screened positive at the 
second TTG screening. Furthermore, a biopsy was performed for the 3 subjects who 
screened positive for TTG. The 2 subjects who screened positive at the first and second 
TTG had positive duodenal biopsy. However, the subject who screened positive at the 
first TTG and negative at the second TTG had a negative duodenal biopsy.  
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Table 16: Descriptive Statistics for Subjects Who Were Screened More than Once 
for TTG 
Variable Results 
Sex  
Female N (%) 
 
F 6 (46%) 
Age 
Median (IQR) 
 
18 years (18) 
Insulin  
N (%) 
 
13 (100%) 
DKA 
N (%) 
 
8 (62%) 
Diabetes antibodies 
N (%) 
GAD65 positive 
Islet cell antibodies positive 
GAD65 and Islet cell antibodies positive 
 
 
10 (77%) 
1 (8%) 
2 (15%) 
Follow up duration 
Median (IQR) 
 
5.3 years (7.2) 
Duration between diabetes diagnosis CD 
screening 
Median (range) 
Diabetes and first TTG 
Diabetes and second TTG 
First and second TTG 
 
 
17 months (0 - 535) 
58 months (1 - 570) 
30 months (1 - 123) 
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Table 17. Detailed Information About the 13 Subjects Who Were Screened for TTG More than Once 
 
# Age a Sex FUY b IgA TTG-1 c D-1 d TTG-2 D-2 TTG-3 D-3 EMA  D-4 e Gliadin CDB f 
1 46 M 4.2 415 N 17 N 51 - - N 17 - - 
2 21 M 5.3 - N 55 N 58 - - - - - - 
3 30 M 15.9 464 P 535 P 570 N 632 - - P P 
4 34 M 12.7 53 N 85 N 90 - - - - N - 
5 7 F 15.1 - N 253 N 318 - - - - - - 
6 38 F 0.9 - N 0 N 1 - - - - N - 
7 12 F 9 191 N 45 N 97 - - - - - - 
8 18 F 10.4 251 N 1 N 124 N 124 - - P - 
9 30 M 7.7 - N 39 N 91 - - - - - - 
10 13 F 3.5 192 N 14 N 44 - - N 14 - - 
11 12 M 3 163 N 12 N 24 N 36 - - - - 
12 5 M 3.2 152 P 12 P 21 P 26 - - - P 
13 16 F 2.2 94 P 13 N 38 - - - - N N 
a Age: Age at diabetes diagnosis. 
b FUY:  Duration from the first A1C to the last A1C done at BMC in Years. 
c TTG-1:  Results for first anti-tissue transgluataminase antibodies screening (N  = Negative, P = Positive). 
d D-1: Duration between diabetes diagnosis and TTG1 in months. 
e D-4: Duration between diabetes diagnosis and EMA in months. 
f CDB:  Results of duodenal biopsy (N = Negative, P = Positive). 
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DISCUSSION 
 
 This retrospective cohort study investigated the difference in glycemic control 
between subjects who screened negative for CD and subjects who screened positive for 
CD among subjects with autoimmune type1 diabetes. Also, this study explored the 
association between CD screening results and diabetes antibodies results. For this reason, 
longitudinal data between January 2000 and November 2015 was obtained from pre-
existing health care data at BMC through the CDW.  
 The prevalence of potential CD based on a positive TTG screening in this study 
was 8.8% while the prevalence of confirmed CD was 4.4%. This prevalence was similar 
to what was reported in other studies.45-48 This is important because this indicate that the 
study population was representative of the general diabetic population. Therefore, the 
findings of this study can be generalized to the general diabetic population. 
 
Glycemic Control 
 Glycemic control was found to be better for subjects with a positive TTG screen 
compared to subjects with a negative TTG screen. Subjects who screened positive for 
TTG had mean A1C concentrations lower than subjects who screened negative for TTG 
over the study follow up period. However, the difference was significant only using the 
GEE models but not the mixed-effects models. For this reason, the findings in this study 
were considered not statistically significant. Moreover, no difference in glycemic control 
was found in the secondary analysis that compared subjects who had positive CD biopsy 
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to subjects who screened negative for TTG. Thus, the clinical implications for physicians 
who treat patients with type1 diabetes is that the clinical management should be the same 
regardless of whether or not a diabetic is diagnosed with CD.  
 The findings of this study were similar to most of the other published studies. 
First, Simmons et al looked at glycemic control between subjects with both CD and type1 
diabetes and subjects with type1 diabetes alone at baseline, 1 year, and 2 years and found 
no difference between the cohorts over the study period.30 Bakker et al looked for a 
difference in glycemic control at three time points, which included before the moment of 
CD diagnosis, at the moment of CD diagnosis, and at the most recent visit, and found no 
difference in glycemic control between the two cohorts.25 Also, Taler et al did not find a 
significant difference in glycemic control between the two cohorts.31 Of note, the follow 
up duration in Taler et al was similar to the follow up duration in the present study (more 
than 10 years). Mackinder et al looked at the glycemic control 2 years before CD 
diagnosis and 2 years after diagnosis and found no difference in glycemic control 
between subjects with both diabetes and CD, and subjects with diabetes alone over the 
entire period.29 Even though the present study had a smaller sample size compared to the 
previous studies, the results remain consistent. Therefore, the present study adds to the 
knowledge that there is no difference in glycemic control between diabetics who are 
diagnosed with CD and diabetics who are not diagnosed with CD. 
 While the aforementioned findings are promising, a few studies have reported 
different results. Leeds et al reported that subjects with both diabetes and confirmed CD 
exhibited worse glycemic control compared to subjects with diabetes alone.20 However, 
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this observation was based on a single time point. The present study and the studies 
mentioned above examined glycemic control over at least two years of follow up and 
concluded that there was no difference in glycemic control. This highlights the fact that 
when investigating glycemic control in diabetic subjects one should look at the glycemic 
control longitudinally because A1C levels fluctuate overtime depending on the patient 
clinical condition.11 
 Another observation in the present study was that the mean A1C level for subjects 
with a negative screening for CD was higher than what was reported in previous studies. 
The majority of the studies reported that subjects with a negative CD screen had a mean 
A1C level of approximately 8.3%.29-31 In contrast, the mean A1C level for the same 
cohort in the present study was 9.3% and 8.9% in the unadjusted models and in the 
adjusted models, respectively. This might be due to the influence of unmeasured 
confounders that should have been included in the model during analysis. Unfortunately, 
these confounders were not collected as part of this study, which is a limitation of the 
study’s design. Moreover, in the present study and the previous studies that did not find 
any statistically significant difference in glycemic control between cohorts, the mean 
A1C levels were lower for subjects with positive CD compared to subjects with negative 
CD. This means that there could be a significant difference in glycemic control between 
the two cohorts; however, the studies were underpowered to detect this difference. Thus, 
sample size and power calculation should be considered when planning future studies. 
 Moreover, the earlier observation regarding the presence of a significant 
difference in mean A1C levels between the subjects who screen positive for CD and 
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subjects who screen negative for CD can be explained physiologically. Glucose 
absorption from the GI tract was found to be lower in non-diabetic subjects with 
untreated malabsorptive disorders, including CD.49,50 Thus, diabetics with untreated CD, 
in theory, would be expected to have lower glucose absorption, lower blood glucose 
concentration, and ultimately lower A1C levels compared to diabetics with no CD.  
However, this might not be true in clinical care for diabetics who are diagnosed with CD 
because glycemic control in these patients is more complex and differs on case-by-case 
bases.51 
 Additionally, glycemic control can be affected by whether the subject was on 
GFD or not. Sun et al found that subjects with both diabetes and CD had lower A1C 
levels before the initiation of GFD compared to subjects with diabetes alone; however, 
A1C levels increased for subjects with CD after the initiation of GFD and the difference 
between the two cohorts has become not significant.28 This can be explained by the fact 
that GFD has high glycemic load and high glycemic index 52, which means that GFD 
elevate the blood glucose concentration rapidly and to higher concentration than regular 
diet. On the contrary to Sun et al, Simons et al30 and Taler et al31 did not find any 
difference in A1C levels for subjects with CD who were on GFD compared to subjects 
who were on regular diet. Unfortunately, the present study had no data about GFD for the 
subjects with positive CD. This was mainly due to the fact that compliance with GFD can 
be challenging for patients with CD and patients adherence level would not be constant 
over a long period of time.18 For this reason, the retrospective nature of this study made it 
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difficult to obtain data for GFD; this would be best suited for a prospective cohort study 
design. 
 
Diabetes Antibodies and Risk for Positive CD Screening 
 This study examined the association between different diabetes antibodies, 
GAD65, Islet cell antibodies, and both, and TTG screenings and found no association 
between the two. This finding was consistent with what was reported in the literature. 
Hansson et al looked at the association between diabetes antibodies, GAD65 and tyrosine 
phosphatase (IA-2), and TTG levels and found no significant correlation.53 Also, Kakleas 
et al did not find any significant difference in the proportion of subjects who screened 
positive for GAD65 between subjects who screened positive and subjects who screened 
negative for TTG.47 Furthermore, Glastras et al followed up 173 subjects for up to 13 
years after diabetes diagnosis.41 They did not find any significant increase in risk for 
positive CD screening among subjects who had positive diabetes antibodies at the time of 
diabetes diagnosis. However, they used EMA and Gliadin for CD screening while the 
present study only included TTG in the analysis. The findings in this study and the other 
studies support the fact that the risk for developing CD is the same for different diabetes 
antibodies. Accordingly, all patients should be screened for CD at the same frequency 
regardless of their diabetes antibody status. 
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Frequency of CD Screening 
 The third objective of this study was to determine the screening frequency of CD 
for diabetic subjects. Unfortunately, there was insufficient numbers of subjects and 
follow up duration information to perform formal statistical testing for this objective. 
There were only 13 subjects in the study population who were screened more than once 
for TTG. Thus, descriptive statistics were used to examine the data and to provide 
information that can be used for the development of future studies. 
 In this study, 3 adult subjects were screened for TTG after 5 years of diabetes 
duration (Table 17), one subject was first screened after 7 years, another one after 21 
years, and the last subject was screened after 44 years from the time of diabetes 
diagnosis; the one who was screened after 44 years had a positive TTG results and a 
positive CD biopsy. These findings support the fact that CD screening should be 
considered not only at the time of diabetes diagnosis, but also periodically over time as 
CD may develop in time. 
 Moreover, in the present study, there was one subject who initially screened 
positive for TTG but then a repeated test 2 years later was negative. The same subject 
underwent duodenal biopsy and found to be negative for CD. It has been reported in the 
literature that diabetic patients might have a period of transient positivity for CD 
antibodies and that GFD and biopsy should be delayed. Waisbourd-Zinman et al followed 
48 subjects with positive TTG and found that in 17 (35%) subjects the TTG levels 
became normal after a median of 6 months.54 Similarly, Castellaneta et al reported that 
CD antibodies normalized in 20% of the subjects who screened positive for CD.55 
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However, 3 subjects in the aforementioned study became positive again. Accordingly, the 
findings in this study and the other two studies highlight the fact that duodenal biopsy 
should be delayed to avoid any unnecessary harm associated with the procedure. 
 
Limitations 
 The present study has several limitations. First, the sample size in this study was 
not large enough to detect any significant difference in mean A1C levels between the 
study cohorts. For example, the positive TTG cohort had only 6 subjects with 111 study 
visits compared to 62 subjects with 805 study visits in the negative TTG cohort. In 
general, a small sample size decreases the power of the study and increases the chance for 
type II error, failing to reject the null hypothesis when there is a true difference between 
the study cohorts.56 Thus, a post hoc power calculation was conducted using the SIMR 
package57 in R and it showed that the study was underpowered to detect a significant 
difference. The study had a 35% power (CI 32 - 38) to significantly detect a 1.0 point 
difference in A1C level between the cohorts; the power was calculated using 1000 
simulations. So, if in realty there was a difference in mean A1C levels between the study 
cohorts, this study might have missed it. 
 The reduced power in this study can be partly explained by the unequal 
distribution of the number of subjects between the cohorts. Accordingly, a post hoc 
sample size calculation was done based on the outcomes of the unadjusted mixed-effects 
model using the SIMR R package.57 The calculation was based on the following 
parameters: 1.9 random intercept variance, 2.5 residual variance, 0.3 delta, 5% alpha, 
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80% power, and 8 study visits for each subject. The results are presented in Figure 4. It 
showed that at least 15 subjects should have been included (8 in each cohort) in order to 
have 80% power to detect a 0.3 difference in A1C levels. 
 
 
Figure 4. Power Chart for Sample Size 
 
 Another limitation in this study was limited data availability for potential 
confounders. First, weight is a potential confounder that has an effect on glycemic 
control. Overweight and obesity were found to be associated with poor glycemic 
control.58 Additionally, race has an impact on glycemic control. Black and Hispanic had 
worse glycemic control when compared to white Non-Hispanic.58,59 Another potential 
confounder is socioeconomic status. Diabetics who had annual household income of 
$50,000 or more had better glycemic control than subjects who had less annual 
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income.58,59 This effect is mainly due to differences in access to care.51 Also, patients 
who are on insulin pump tend to have lower A1C levels compared to patients who are 
using injections for insulin delivery.59 Finally, use of Continuous Glucose Monitoring 
(CGM) is another potential confounder that can affect A1C levels.11,59 CGM is a device 
used to get real-time data of interstitial glucose level, and it was found to be an effective 
way to lower A1C level for diabetic subjects to achieve better glycemic control.11 If data 
about these confounders was available and controlled for during the analysis, then this 
would increase the external validity of the models and the generalizability of the results.  
 This study might have been affected by subject allocation bias due to missing IgA 
level measurements in approximately half of the subjects. In general, guidelines 
recommend measuring IgA levels prior to screening diabetics for CD.32,33,35 This is 
because diabetics have high prevalence of IgA deficiency that can affect the 
interpretation of the screening test. Accordingly, a patient with IgA deficiency will not 
screen positive for an IgA based screening test; an IgG based screening test should be 
performed instead.32,33 In the present study, CD screening tests were IgA based, and IgA 
levels were measured only in 38 subjects of the study population (70 subjects). Thus, if 
any of the 32 subjects who were missing IgA level had IgA deficiency, then he/she would 
have screened negative and mistakenly assigned to the non-exposed cohort. This might 
have affected the results either by increasing or decreasing the glycemic difference 
between the two cohorts. 
 The last limitation for this study is that all the time points were included in the 
analysis; data was not separated to before CD screening and after CD screening. This 
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might have masked the effect of CD on glycemic control if there was any. However, this 
was unlikely because the plot shown in Figure 3 had no significant changes in A1C levels 
for subjects who screened positive over the study period, which means that time of CD 
screening had no effect on A1C level. 
 
Future Studies 
 Future studies are needed to confirm the findings of this study. A prospective 
cohort study with relatively equal number of subjects in each cohort would be the most 
appropriate next step. First, equal number of subjects would increase the power of the 
study to capture any significant difference between the two cohorts. Also, the prospective 
directionality would help in collecting some of the confounders that would have effects 
on the subjects' A1C level. Furthermore, the effect of GFD on glycemic status was not 
assessed in this study. GFD has high glycemic index and high glycemic load52; however, 
this depends on the composition of the diet.60,61 Thus, it would be important to conduct a 
prospective cohort study with a large number of CD subjects to compare the glycemic 
control for subjects who are on GFD to subjects who are on regular diet. The prospective 
cohort design would allow the investigators to record accurate data for subjects' 
adherence to GFD and for the composition, glycemic load, and glycemic index of the 
GFD. 
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Conclusion 
 This study investigated the effect of positive CD screening test and positive CD 
biopsy on glycemic control among type1 diabetic subjects. Longitudinal A1C levels were 
obtained from the CDW at BMC for diabetic subjects who were screened for CD. No 
significant difference was found in mean A1C levels between the two cohorts; positive 
CD and negative CD, respectively. Also, this study investigated the risk for a positive CD 
screening in subjects who screened positive for GAD65, Islet cell antibodies, or both and 
found no increase in risk. Unfortunately, there were not enough subjects in this study to 
investigate frequency of CD screening for diabetic subjects; however, it provided some 
information for a future study development. Even though the study was underpowered to 
detect any significant difference in glycemic control between the two cohorts, the results 
were consistent with most of the other studies.25,30,31 The results of the current study add 
to the knowledge that there is no difference in glycemic control between type1 diabetics 
who screen positive for CD or have biopsy confirmed CD and patients who screen 
negative for CD. This is important with respect to the clinical management of diabetes, as 
this helps guide physicians when considering treatment options. 
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APPENDIX 
 
Table A1. Screened vs. not screened for CD 
Variable Not Screened 
(N=234) 
Screened 
(N=70) 
Sex a 
Female N (%) 
 
106 (45%) 
 
36 (51%) 
Age at diabetes diagnosis b 
Median (IQR) 
 
26 years (25)  
 
17 years (16.3) 
Age at first BMC visit b 
Median (IQR) 
 
31 years (24.8) 
 
22 years (21) 
DKA a 
N (%) 
 
89 (38%) 
 
33 (47%) 
Follow-up a 
Median (IQR) 
 
2.8 years (6.5)  
 
3.4 years (7.5) 
Number of visits a,c 
Median (IQR) 
 
7 visits (12.8) 
 
10 visits (13.8) 
Year of first BMC visit a 
Median (IQR) 
 
2009 (7) 
 
2011 (7) 
a The difference is not statistically significant (p >0.05) 
b The difference is statistically significant (p <0.05) 
c Visits corresponds to the visit at which A1C test was done. 
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